Market Place
Sourcing Support
Ligand to Acquire APEIRON Biologics AG for $100 Million
08 Jul 2024 //
BUSINESSWIRE
APEIRON Respiratory Therapies announces results from PI trial of inhaled APN01
02 Nov 2022 //
GLOBENEWSWIRE
APEIRON shareholders approve new group structure geared towards
25 Apr 2022 //
GLOBENEWSWIRE
Apeiron Biologics begins phase 1 trial to treat Covid-19 with inhaled APN01
13 Oct 2021 //
PHARMABIZ
Apeiron Biologics begins phase 1b trial of APN401 for treatment of solid tumors
07 Jul 2021 //
PHARMABIZ
Apeiron announces phase 2 trial of APN01 shows clinical benefits
15 Mar 2021 //
PHARMABIZ
Expansion of APEIRON Biologics and Domainex Partnership will Advance
25 Nov 2020 //
PHARMTECH
Expansion of APEIRON Biologics and Domainex Partnership will Advance Cancer
24 Nov 2020 //
PHARMTECH
Apeiron Biologics Selects Domainex to Provide Integrated Lead Optimization
12 Nov 2020 //
PHARMTECH
APEIRON Biologics & Domainex announce the expansion of their partnership
09 Nov 2020 //
PRESS RELEASE
THE LANCET publishes promising data of APEIRON`s APN01 (rhsACE2)
24 Sep 2020 //
PRNEWSWIRE
New investors Thiel and Novogratz introduced to Bionomics by Apeiron
03 Sep 2020 //
PRNASIA
APEIRON, MaxCyte Enter Licensing Agreement for APN401
09 Jul 2020 //
CONTRACTPHARMA
APEIRON Biologics and MaxCyte Enter into Clinical, Commercial Agreement APN401
07 Jul 2020 //
PRNEWSWIRE
Recapitalisation Led by Sophisticated Life Sciences Investor - Apeiron Inv Group
02 Jun 2020 //
BUSINESSWIRE
Apeiron Biologics gets regulatory approvals for Phase II Covid-19 trial
02 Apr 2020 //
CLINICALTRALSARENA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.